Effect of an Electronic Medication Reconciliation Intervention on Adverse Drug Events: A Cluster Randomized Trial

Robyn Tamblyn, Michal Abrahamowicz, David L Buckeridge, Melissa Bustillo, Alan J Forster, Nadyne Girard, Bettina Habib, James Hanley, Allen Huang, Siyana Kurteva, Todd C Lee, Ari N Meguerditchian, Teresa Moraga, Aude Motulsky, Lina Petrella, Daniala L Weir, Nancy Winslade, Robyn Tamblyn, Michal Abrahamowicz, David L Buckeridge, Melissa Bustillo, Alan J Forster, Nadyne Girard, Bettina Habib, James Hanley, Allen Huang, Siyana Kurteva, Todd C Lee, Ari N Meguerditchian, Teresa Moraga, Aude Motulsky, Lina Petrella, Daniala L Weir, Nancy Winslade

Abstract

Importance: Adverse drug events (ADEs) account for up to 16% of emergency department (ED) visits and 7% of hospital admissions. Medication reconciliation is required for hospital accreditation because it can reduce medication discrepancies, but there is no evidence that reducing discrepancies reduces ADEs or other adverse outcomes.

Objective: To evaluate whether electronic medication reconciliation reduces ADEs, medication discrepancies, and other adverse outcomes compared with usual care.

Design, setting, and participants: This cluster randomized trial involved 3491 patients who were discharged from 2 medical units and 2 surgical units at the McGill University Health Centre, Montreal, Quebec, Canada, between October 2014 and November 2016. Data analysis took place from July 2017 to July 2019.

Intervention: The RightRx intervention electronically retrieved community drugs from the provincial insurer and aligned them with in-hospital drugs to facilitate reconciliation and communication at care transitions.

Main outcomes and measures: The primary outcome was ADEs in 30 days after discharge. Secondary outcomes included medication discrepancies, ED visits, hospital readmissions, and a composite outcome of ED visits, readmissions, and death up to 90 days after discharge.

Results: Of 4656 eligible patients, 3567 (76.6%) consented to participate (2060 [57.8%] men; mean [SD] age, 69.8 [14.9] years). Overall, 76 patients died during the hospital stay, so 3491 patients were included in the analysis. There was no significant difference in the risk of ADEs between intervention and control groups (76 [4.6%] vs 73 [4.0%]; OR, 0.97; 95% CI, 0.33-1.48), ED visits (433 [26.2%] vs 488 [26.6%]; OR, 0.83; 95% CI, 0.36-1.42), hospital readmission (170 [10.3%] vs 261 [14.2%]; OR, 0.22; 95% CI, 0.06-1.14), or the composite outcome (447 [27.0%] vs 506 [27.6%]; OR, 0.75; 95% CI, 0.34-1.27) at 30 days. Medication discrepancies were significantly reduced in the intervention group compared with the control group (437 [26.4%] vs 1029 [56.0%]; OR, 0.24; 95% CI, 0.12-0.57). Changes made to community medications (OR, 1.05; 95% CI, 1.01-1.10) and new medications (OR, 1.09; 95% CI, 1.01-1.18) were significant risk factors for ADEs.

Conclusions and relevance: Electronic medication reconciliation reduced medication discrepancies but did not reduce ADEs or other adverse outcomes. Hospital accreditation should focus on interventions that reduce the risk of adverse events for patients with multiple changes to community medications.

Trial registration: ClinicalTrials.gov identifier: NCT01179867.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Lee reported receiving grants from the Canadian Institutes of Health Research during the conduct of the study; holding a patent to the RightRx software pending; and receiving research salary support from the Fonds de Recherche Québec—Santé. Dr Winslade reported receiving grants from the Canadian Institutes of Health Research during the conduct of the study. No other disclosures were reported.

Figures

Figure.. Flow Diagram of Patients Included in…
Figure.. Flow Diagram of Patients Included in the RightRx Trial

References

    1. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6):-. doi:10.1067/mem.2001.119456
    1. Zed PJ, Abu-Laban RB, Balen RM, et al. . Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178(12):1563-1569. doi:10.1503/cmaj.071594
    1. Hohl CM, Robitaille C, Lord V, et al. . Emergency physician recognition of adverse drug-related events in elder patients presenting to an emergency department. Acad Emerg Med. 2005;12(3):197-205. doi:10.1197/j.aem.2004.08.056
    1. Hohl CM, Zed PJ, Brubacher JR, Abu-Laban RB, Loewen PS, Purssell RA. Do emergency physicians attribute drug-related emergency department visits to medication-related problems? Ann Emerg Med. 2010;55(6):493-502.e4. doi:10.1016/j.annemergmed.2009.10.008
    1. Bates DW, Cullen DJ, Laird N, et al. ; ADE Prevention Study Group . Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274(1):29-34. doi:10.1001/jama.1995.03530010043033
    1. Kwan JL, Lo L, Sampson M, Shojania KG. Medication reconciliation during transitions of care as a patient safety strategy: a systematic review. Ann Intern Med. 2013;158(5 Pt 2):397-403. doi:10.7326/0003-4819-158-5-201303051-00006
    1. Michaelsen MH, McCague P, Bradley CP, Sahm LJ. Medication reconciliation at discharge from hospital: a systematic review of the quantitative literature. Pharmacy (Basel). 2015;3(2):53-71. doi:10.3390/pharmacy3020053
    1. Mekonnen AB, Abebe TB, McLachlan AJ, Brien JA. Impact of electronic medication reconciliation interventions on medication discrepancies at hospital transitions: a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2016;16(1):112. doi:10.1186/s12911-016-0353-9
    1. Mekonnen AB, McLachlan AJ, Brien JA. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41(2):128-144. doi:10.1111/jcpt.12364
    1. Accreditation Canada, Canadian Institute for Health Information, Canadian Patient Safety Institute, Institute for Safe Medication Practices Canada . Medication Reconciliation in Canada: Raising The Bar—Progress to Date and the Course Ahead. Ottawa, ON: Accreditation Canada; 2012.
    1. The Joint Commission National patient safety goals effective January 2018. f. Accessed July 25, 2019.
    1. Abdellatif A, Bagian JP, Barajas ER, et al. . Assuring medication accuracy at transitions in care. Jt Comm J Qual Patient Saf. 2007;33(7):450-453. doi:10.1016/S1553-7250(07)33131-0
    1. Leotsakos A, Zheng H, Croteau R, et al. . Standardization in patient safety: the WHO High 5s project. Int J Qual Health Care. 2014;26(2):109-116. doi:10.1093/intqhc/mzu010
    1. Institute of Healthcare Improvement How-to Guide: Prevent Adverse Drug Events by Implementing Medication Reconciliation. Cambridge, MA: Institute for Healthcare Improvement; 2011.
    1. Meguerditchian AN, Krotneva S, Reidel K, Huang A, Tamblyn R. Medication reconciliation at admission and discharge: a time and motion study. BMC Health Serv Res. 2013;13:485-485. doi:10.1186/1472-6963-13-485
    1. Tamblyn R, Winslade N, Lee TC, et al. . Improving patient safety and efficiency of medication reconciliation through the development and adoption of a computer-assisted tool with automated electronic integration of population-based community drug data: the RightRx project. J Am Med Inform Assoc. 2018;25(5):482-495. doi:10.1093/jamia/ocx107
    1. Marien S, Krug B, Spinewine A. Electronic tools to support medication reconciliation: a systematic review. J Am Med Inform Assoc. 2017;24(1):227-240. doi:10.1093/jamia/ocw068
    1. Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med. 2012;172(14):1057-1069. doi:10.1001/archinternmed.2012.2246
    1. Lehnbom EC, Stewart MJ, Manias E, Westbrook JI. Impact of medication reconciliation and review on clinical outcomes. Ann Pharmacother. 2014;48(10):1298-1312. doi:10.1177/1060028014543485
    1. Polinski JM, Moore JM, Kyrychenko P, et al. . An insurer’s care transition program emphasizes medication reconciliation, reduces readmissions and costs. Health Aff (Millwood). 2016;35(7):1222-1229. doi:10.1377/hlthaff.2015.0648
    1. Ravn-Nielsen LV, Duckert ML, Lund ML, et al. . Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission: a randomized clinical trial. JAMA Intern Med. 2018;178(3):375-382. doi:10.1001/jamainternmed.2017.8274
    1. Zemaitis CT, Morris G, Cabie M, Abdelghany O, Lee L. Reducing readmission at an academic medical center: results of a pharmacy-facilitated discharge counseling and medication reconciliation program. Hosp Pharm. 2016;51(6):468-473. doi:10.1310/hpj5106-468
    1. McGill University Health Centre Moving forward together: the MUHC 2015-2016 annual report. . Accessed July 25, 2019.
    1. Tamblyn R, Huang AR, Meguerditchian AN, et al. . Using novel Canadian resources to improve medication reconciliation at discharge: study protocol for a randomized controlled trial. Trials. 2012;13:150. doi:10.1186/1745-6215-13-150
    1. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events occurring following hospital discharge. J Gen Intern Med. 2005;20(4):317-323. doi:10.1111/j.1525-1497.2005.30390.x
    1. Tamblyn R, Huang A, Perreault R, et al. . The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ. 2003;169(6):549-556.
    1. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol. 1995;48(8):999-1009. doi:10.1016/0895-4356(94)00234-H
    1. Mitchell AS, Henry DA, Hennrikus D, O’Connell DL. Adverse drug reactions: can consumers provide early warning? Pharmacoepidemiol Drug Saf. 1994;3(5):257-264. doi:10.1002/pds.2630030504
    1. Leape LL, Bates DW, Cullen DJ, et al. ; ADE Prevention Study Group . Systems analysis of adverse drug events. JAMA. 1995;274(1):35-43. doi:10.1001/jama.1995.03530010049034
    1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795-801. doi:10.7326/0003-4819-140-10-200405180-00009
    1. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol. 1993;46(5):423-429. doi:10.1016/0895-4356(93)90018-V
    1. Tamblyn R, Poissant L, Huang A, et al. . Estimating the information gap between emergency department records of community medication compared to on-line access to the community-based pharmacy records. J Am Med Inform Assoc. 2014;21(3):391-398. doi:10.1136/amiajnl-2013-001704
    1. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD index 2019. . Published 2018. Accessed August 6, 2018.
    1. Régie de l’assurance maladie du Québec 2000 Statistiques Annuelles. Québec City, QC: Régie de l’assurance maladie du Québec; 2000.
    1. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55. doi:10.1093/biomet/70.1.41
    1. Venkatesh V, Bala H. Technology acceptance model 3 and a research agenda on interventions. Decis Sci. 2008;39(2):273-315. doi:10.1111/j.1540-5915.2008.00192.x
    1. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251. doi:10.1016/0895-4356(94)90129-5
    1. Quan H, Li B, Couris CM, et al. . Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682. doi:10.1093/aje/kwq433
    1. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27. doi:10.1097/00005650-199801000-00004
    1. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-1156. doi:10.1093/aje/kwj149
    1. Lee J, Little TD. A practical guide to propensity score analysis for applied clinical research. Behav Res Ther. 2017;98:76-90. doi:10.1016/j.brat.2017.01.005
    1. Kahan BC, Forbes G, Ali Y, et al. . Increased risk of type I errors in cluster randomised trials with small or medium numbers of clusters: a review, reanalysis, and simulation study. Trials. 2016;17(1):438-438. doi:10.1186/s13063-016-1571-2
    1. Li P, Redden DT. Comparing denominator degrees of freedom approximations for the generalized linear mixed model in analyzing binary outcome in small sample cluster-randomized trials. BMC Med Res Methodol. 2015;15:38. doi:10.1186/s12874-015-0026-x
    1. Leyrat C, Morgan KE, Leurent B, Kahan BC. Cluster randomized trials with a small number of clusters: which analyses should be used? Int J Epidemiol. 2018;47(1):321-331. doi:10.1093/ije/dyx169
    1. Xiao Y, Abrahamowicz M. Bootstrap-based methods for estimating standard errors in Cox’s regression analyses of clustered event times. Stat Med. 2010;29(7-8):915-923. doi:10.1002/sim.3807
    1. Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA. 2014;312(22):2401-2402. doi:10.1001/jama.2014.16153
    1. Robinson S, Howie-Esquivel J, Vlahov D. Readmission risk factors after hospital discharge among the elderly. Popul Health Manag. 2012;15(6):338-351. doi:10.1089/pop.2011.0095
    1. Preyde M, Brassard K. Evidence-based risk factors for adverse health outcomes in older patients after discharge home and assessment tools: a systematic review. J Evid Based Soc Work. 2011;8(5):445-468. doi:10.1080/15433714.2011.542330
    1. Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T. Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. Arch Intern Med. 2004;164(5):545-550. doi:10.1001/archinte.164.5.545
    1. van den Bemt PMLA, Egberts ACG, Lenderink AW, et al. . Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000;22(2):62-66. doi:10.1023/A:1008721321016
    1. Jack BW, Chetty VK, Anthony D, et al. . A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150(3):178-187. doi:10.7326/0003-4819-150-3-200902030-00007
    1. Coffey M, Cornish P, Koonthanam T, Etchells E, Matlow A. Implementation of admission medication reconciliation at two academic health sciences centres: challenges and success factors. Healthc Q. 2009;12(Spec No Patient):102-109.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다